European Patent Office

R 0021/09 of 19.03.2010

European Case Law Identifier
ECLI:EP:BA:2010:R002109.20100319
Date of decision
19 March 2010
Case number
R 0021/09
Petition for review of
T 1753/06 2009-05-06
Application number
01954058.2
IPC class
C07D 209/42
Language of proceedings
French
Distribution
Distributed to board chairmen and members (B)
OJ versions
No OJ links found
Other decisions for this case
-
Abstracts for this decision
-
Application title
Forme cristalline alpha du sel de tert-butylamine du perindopril
Applicant name
Les Laboratoires Servier
Autres Parties :
Quimica Sintetica. S.A.
NORTON HEALTHCARE LTD
Glenmark Pharmaceuticals Ltd
POLPHARMA
MIESZKOWSKA, Agnieszka, AMCA Consulting
Hetero Drugs Limited
Ratiopharm GmbH
Opponent name
-
Board
-
Headnote
-
Relevant legal provisions
European Patent Convention Art 112aEuropean Patent Convention Art 113European Patent Convention Art 23(3)European Patent Convention R 106European Patent Convention R 109High Court of Justice - Court of Appeal (Civil Division): Actavis UK Limited v. Novartis AG (A3/2009/0675)Rules of procedure of the Boards of Appeal Art 17(2)
Keywords
Violation fondamentale de procédure: non respect du droit de se défendre - Art. 113 CBE [non]
Requête en révision - manifestement non fondée
Catchword
-
Cited cases
T 0452/91

DISPOSITIF

Par ces motifs, il est statué comme suit :

La requête en révision est rejetée comme manifestement non fondée.